UK generic competition is finally set to materialize for AstraZeneca’s Forxiga (dapagliflozin) blockbuster treatment for diabetes, after the country’s Supreme Court removed the last barrier for rivals
With plans to launch 20 biosimilars and bring a total of eight to market by 2027, Teva says that not all its biosimilars need to be “superstars,” as it remains confident of doubling 2024 biosimilar r
A decade after Teva’s largest-ever deal, the $40.5bn purchase of Allergan’s Actavis Generics unit, the shadow of that transaction continues to loom over the Israeli group. “In the past, after the Acta
Accord Healthcare, Sandoz and Teva have failed to convince the Court of Appeal of England and Wales to overturn a lower court order that the UK part of a key patent shielding Astellas’ $6.2bn Xtandi (